Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO044 extension study in Duchenne muscular dystrophy
NL-OMON41314Phase 2Active, not recruiting
- Sponsor
- Prosensa
- Start
- Jul 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PRO044 in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Prosensa. Primary endpoint: Safety, tolerability and efficacy. Started Jul 2015; status: active, not recruiting.
02
Drugs
PRO044
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON41314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41314.